Market Place
Sourcing Support
Bristol’ schizophrenia drug nears approval, AbbVie hope to provide competition
19 Aug 2024 //
BIOPHARMADIVE
AbbVie Completes Acquisition of Cerevel Therapeutics
01 Aug 2024 //
PR NEWSWIRE
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
19 Apr 2024 //
BIOPHARMADIVE
Cerevel`s Tavapadon Meets Phase 3 Adjunctive Parkinson`s Trial Goals
18 Apr 2024 //
GLOBENEWSWIRE
Cerevel Therapeutics is lower by 3.66% Tuesday In Premarket Trading
01 Feb 2024 //
INVESTOR OBSERVER
AbbVie to acquire Cerevel for $8.7 billion
07 Dec 2023 //
REUTERS
Cerevel to Host Investor Webcast on Tavapadon in Parkinson™s Disease
29 Nov 2023 //
GLOBENEWSWIRE
Cerevel to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
23 Nov 2023 //
PRESS RELEASE
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results
16 Nov 2023 //
PRESS RELEASE
Cerevel Therapeutics to Present at Upcoming Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Cerevel Reports Third Quarter 2023 Financial Results and Business Updates
01 Nov 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results
13 Oct 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
11 Oct 2023 //
GLOBENEWSWIRE
Cerevel Announces Pricing of $450 Million Public Offering of Common Stock
11 Oct 2023 //
GLOBENEWSWIRE
Cerevel to Present at Morgan Stanley 21st Annual Healthcare Conference
29 Aug 2023 //
GLOBENEWSWIRE
Cerevel Reports Second Quarter 2023 Financial Results and Business Updates
02 Aug 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results
05 Jul 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics Appoints Paul Burgess as CBD & SOO
15 Jun 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as CFO
10 May 2023 //
GLOBENEWSWIRE
Cerevel hires former Translate Bio head Renaud as new CEO
04 May 2023 //
BIOPAHRAMDIVE
Cerevel Therapeutics Appoints Ron Renaud as President & CEO Reports 1Q 2023 FYR
03 May 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at the BofA Securities 2023 Conference
26 Apr 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics to Report First Quarter 2023 Financial Results
11 Apr 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
21 Mar 2023 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
02 Mar 2023 //
GLOBENEWSWIRE
Cerevel Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
GLOBENEWSWIRE
Cerevel blames Covid for delayed neuroscience studies, says president is leaving
22 Feb 2023 //
ENDPTS
Cerevel to Report Fourth Quarter and Full Year 2022 Financial Results
01 Feb 2023 //
GLOBENEWSWIRE
Herophilus Announces Results from Collaboration with Cerevel Therapeutics
24 Jan 2023 //
BUSINESSWIRE
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
09 Jan 2023 //
GLOBENEWSWIRE
Cerevel to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Safety data for Cerevel`s schizophrenia drug de-risks asset
20 Dec 2022 //
FIERCEBIOTECH
Cerevel Announces Results in Emraclidine Ambulatory BP Monitoring Trial
19 Dec 2022 //
GLOBENEWSWIRE
Cerevel Announces Publication in Lancet of Emraclidine Data from Phase 1b Trial
15 Dec 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at Upcoming Investor Conferences
11 Nov 2022 //
GLOBENEWSWIRE
Cerevel Reports Third Quarter 2022 Financial Results and Business Updates
08 Nov 2022 //
PRESS RELEASE
While PhIII Parkinson`s trials go slower, Cerevel previews plans to raise $900M
08 Nov 2022 //
ENDPTS
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results
19 Oct 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at Morgan Stanley 20th Annual GHC
06 Sep 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Announces Pricing of $254 Million Public Offering
12 Aug 2022 //
GLOBENEWSWIRE
Cerevel`s Tony Coles is still counting his money as a rival`s boost helps $609M
12 Aug 2022 //
ENDPTS
Cerevel takes the public offering route, with a twist
11 Aug 2022 //
ENDPOINTS NEWS
Cerevel Therapeutics Announces Proposed PO of Common Stock
10 Aug 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Announces Proposed Private Offering of Convertible
10 Aug 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Reports Q2 2022 Financial Results and Business Updates
01 Aug 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results
25 Jul 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Announces Updates to its Board of Directors
15 Jun 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
25 May 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
RSI Alert: Cerevel Therapeutics Holdings (CERE) Now Oversold
09 May 2022 //
NASDAQ
Cerevel Tx to Report Q1 2022 Financial Results and Pipeline Update
13 Apr 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
31 Mar 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
21 Mar 2022 //
GLOBENEWSWIRE
Cerevel Tx Provides Q4 and Full Year 2021 Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics Announces Positive Topline Results for Darigabat
15 Feb 2022 //
GLOBENEWSWIRE
Cerevel Therapeutics to Present at 40th JPM Conference
10 Jan 2022 //
GLOBENEWSWIRE
Cerevel and Herophilus Announce Collab to Evaluate Neuroimmune
16 Dec 2021 //
GLOBENEWSWIRE
Cerevel Therapeutics CFO Kathy Yi resigns
21 Sep 2021 //
SEEKINGALPHA
Cerevel Report Second Quarter 2021 Financial Results on Wednesday, August 11
22 Jul 2021 //
GLOBENEWSWIRE
Cerevel Report Second Quarter 2021 Financial Results on Wednesday, August 11
22 Jul 2021 //
GLOBENEWSWIRE
